Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries. Dyadic’s C1 platform technology enables the development and large scale manufacture of low cost […]
Search Results for 'dyadic'
For a guy deep in the gene business, ironic that he started off with jeans. Back in the 70s, Dyadic began as a pioneer and leader in providing ingredients used in the stone-washing of blue jeans. Along the way the company developed its pretty awesome C1 fungal microorganism platform that has been licensed by Codexis and Abengoa amongst […]
In Florida, Dyadic International filed a Form 10 with the SEC. If accepted by the SEC (they have 60 days to respond with questions), Dyadic will become a fully reporting public company again. For those newer to the scene, Dyadic imploded in 2006-07 over a series of mishaps relating to an Asian venture, which resulted […]
In Florida, Dyadic International announced that it has signed a collaboration agreement to commercialize second generation biofuel and bio-based chemical technology with Compagnie Industrielle de la Matière Végétale (“CIMV”), a pioneer in developing processes for the production of biofuels and bio-based chemicals. CIMV’s patented approach of separating the three main components of plant material allows […]
In Florida, Dyadic has announced details regarding its new Bakenzyme project. In collaboration with several industry partners, the Bakenzyme project seeks to develop a novel, pure and widely applicable xylanase-oxidase enzyme product for the baking industry. Dyadic’s Chief Operating Officer, Danai Brooks, stated, “The aim of this project is to create an enzyme product that improves […]
In Florida, Dyadic’s gross profit in Q1 of FY2014 has nearly doubled from $520,000 to over $1,000,000 since FY2013, according to the company’s Q1 results announced last week. Revenues also grew 20% in Q1. Regarding the coming months, CEO Mark Emalfarb said, “Dyadic’s technology licensing model is expected to bring us recurring royalty streams in […]
In Florida, Dyadic has announced that it has launched Fibrezyme G4, a high performance cellulase enzyme product designed to enhance paper and textile quality. The enzyme has shown to reduce energy requirements and increase production rates for pulp and paper manufacturers. Dyadic Chief Operating Officer Danai Brooks commented: “We expect two key markets to be […]
In the Netherlands, Dyadic has received a US patent for its C-1 technology that is currently being implemented at Abengoa’s cellulosic ethanol plant that’s getting read to start up in Hugoton, Kan. As Abengoa goes to license its technology package, Dyadic’s C-1 would be the enzyme component. The patent is Dyadic’s 14th.
Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries. Rankings 50 Hottest Companies in Bioenergy: 2013/14, #46 The Situation In their 2013 results, […]
In Florida, Dyadic International has announced their financial results for the FY2013. Total revenue for the company increased 10% for the year compared to FY2012, with net product-related revenue increasing 25% to $9.8 million. The increase was driven primarily by increases in the animal health and nutrition segments, the addition of two major customers and […]